Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
COVID-19-associated mucormycosis: Case report and systematic review

Ahmet Dilek a, b, Resat Ozaras c, Sevket Ozkaya d, e, Mustafa Sunbul f, Elif Itir Sen g, Hakan Leblebicioglu h, *

a Intensive Care Unit, VM Medicalpark Samsun Hospital, Samsun, Turkey
b Istanbul University, Faculty of Medicine, Istanbul, Turkey
c Department of Infectious Diseases, Medilife Health Group, Istanbul, Turkey
d Department of Pulmonology, VM Medicalpark Samsun Hospital, Samsun, Turkey
e Department of Pulmonology, Bahcesehir University Medical School, Istanbul, Turkey
f Department of Infectious Diseases, Samsun Liv Hospital, Samsun, Turkey
g Intern, Bahcesehir University, Medical School, Istanbul, Turkey
h Department of Infectious Diseases, VM Medicalpark Samsun Hospital, Samsun, Turkey

ARTICLE INFO

Keywords:
COVID-19
Coronavirus
Mucormycosis
Mucor
Fungal infections

ABSTRACT

Background: Increasing number of patients with COVID-19-associated mucormycosis have been reported, especially from India recently. We have described a patient with COVID-19-associated mucormycosis and searched and analyzed current medical literature to delineate the characteristics of COVID-19-associated mucormycosis.

Method: We reported a patient developed mucormycosis during post-COVID period. We searched literature to describe the incidence, clinical features, and outcomes of COVID-19-associated mucormycosis. Demographic features, risk factors, clinical features, diagnostic methods, treatment and outcome were analyzed.

Results: We describe a 54-year-old male, hospitalized due to severe COVID-19 pneumonia. He was given long-term, high doses of systemic steroids. He developed maxillo-facial mucormycosis and died of sepsis. Our literature search found 30 publications describing 100 patients including present case report. The majority (n = 68) were reported from India. 76% were male. The most commonly seen risk factors were corticosteroid use (90.5%), diabetes (79%), and hypertension (34%). Also, excessive use of broad-spectrum antibiotics were noted in cases. Most frequent involvements were rhino-orbital (50%), followed by rhino-sinusal (17%), and rhino-orbito-cerebral (15%). Death was reported as 33 out of 99 patients (33.3%).

Conclusions: Steroid use, diabetes, environmental conditions, excessive use of antibiotics, and hypoxia are main risk factors. Despite medical and surgical treatment, mortality rate is high. A multidisciplinary approach is essential to improve the conditions facilitating the emergence of COVID-19-associated mucormycosis.

1. Introduction

New coronavirus disease (COVID-19) continues to exhibit remarkable repercussions worldwide along with its atypical manifestations. Novel reports of SARS-CoV-2 infection underline the risk of opportunistic fungi infections, namely the pulmonary aspergillosis and mucormycosis, that accompany viral symptoms, leading to death by invading multi-organ systems [1]. Experience from SARS patients showed that incidence of fungal co-infection was 14.8–27%, and it was higher in severely ill SARS patients reaching up to 33% [2]. Furthermore, severe influenza pneumonia cases resulting in acute respiratory distress syndrome complicated by fungal infection were reported [3]. While invasive pulmonary aspergillosis was found in 83 (19%) of 432 patients with influenza, it was higher in immunocompromised patients (32%) [4].

The main reason behind invasive fungal infections is thought to be due to the impairment of innate defense mechanisms, such as ciliary clearance, and the lack of sufficient lymphatic immune response against fungal invasion during the pathophysiologic progression of deregulatory immune mechanisms in COVID-19-related acute respiratory distress syndrome (ARDS) [5]. As a matter of fact, utilization of corticosteroids, one of the widely used weapons against COVID-19 to diminish the risk of
mortality, most likely causes critically ill patients in intensive care units (ICU) to be more prone to opportunistic infections, which in turn may lead to death. The exact incidence of fungal involvement is not yet known due to the incapability of common bronchoscopy diagnosis in COVID-19 patients [5]. Since the clinical and radiological findings of secondary fungal infections are not distinguishable from varying COVID-19 pneumonia and pneumonitis, the identification of pathogenic fungi is mainly dependent on the positivity in lower respiratory tract specimen tests, such as the bronchoalveolar lavage, sputum or endotracheal aspirate [5–7].

Specially, COVID-19-associated mucormycosis, an opportunistic fungus that invades rhinal, occipital and cerebral areas, come to light as the pandemic proceeds. Mucormycosis is caused by the fungus Mucor (class Phycomycetes, order Mucorales) that is capable of reaching craniofacial compartments such as paranasal sinuses, pharynx, orbita and intracranial cavity via the spore spread [6]. Thus, the invasion is highly lethal and rapidly progressive, requiring a multidisciplinary approach and fast actions in treatment. Mucor-derived angioinvasion presents as diverse signs and symptoms including nasal stuffiness; mucoid, purulent, bloody or black nasal discharge; epistaxis; facial, nasal or periorcular edema and discoloration, speaking defects, vision impairment and excruciating headache [8]. Predisposing factors were known to be consisting of conditions such as diabetes mellitus, corticosteroid usage and immunosuppression, immunodeficiency, malignancies (especially hemato logic) and cell/tissue/organ transplant treatments [8]. However, COVID-19, which requires a comprehensive and multi-organ-based treatment in varying severities, is unfortunately added to the list of risk factors for the opportunistic Mucor infection.

Increasing number of patients with COVID-19-associated mucormycosis have been reported from India recently. The association of these two critical infectious diseases is challenging not only for India but also for the rest of the World. In this systematic review, in order to delineate the characteristics of COVID-19-associated mucormycosis, we have searched current medical literature and analyzed mucormycosis infection developed in patients with COVID-19.

2. Material and methods

2.1. Search strategies and study selection

Literature search was performed in PubMed, PUBMED, Web of Science, and Scopus according to the PRISMA guidelines [9]. Papers published in any language between December 1, 2019, to June 1, 2021, were included. The literature was searched using keywords of [(COVID 19 OR Coronavirus OR corona) AND (mucormycosis OR mucor)]. The EndNote database was used from importing and managing abstracts and full texts. After first evaluation of the paper, duplicates were removed. Full text papers were evaluated and selected by two independent authors (D.A., M.S.) (Fig. 1). All the authors approved this selection process.

2.2. Inclusion criteria

Case reports, case series, and observational studies describing the incidence, clinical features, and outcomes of mucormycosis developed in COVID-19 patients were included in the systematic review. Case reports without clinical and laboratory features were excluded. Demographic features, risk factors, clinical features, diagnostic methods, treatment and outcome were analyzed.

Fig. 1. Review process of medical literature about COVID-19 and mucormycosis.
2.3. Case definition

Mucormycosis cases were classified as “possible”, “probable” or “proven” according to the recently published guideline of “Code Mucor: Guidelines for the Diagnosis, Staging and Management of Rhino-Orbito-Cerebral Mucormycosis in the Setting of COVID-19” [8]. This guideline describes rhino-orbito-cerebral mucormycosis. For the patients with involvement other than these, the criterion of “probable” was modified to include organ-specific endoscopic procedures and MRI or CT imaging studies.

In brief, among patients with proven COVID-19 infections, presence of typical clinical mucormycosis findings is described as “possible”; in addition to these, presence of nasal/pulmonary/gastrointestinal endoscopic or MRI/CT findings compatible with mucormycosis is described as “probable”; and in addition to these, if mucormycosis is proven by microbiologic, histologic, and molecular methods, it is classified as “proven”. All “probable” and “proven” cases were included into the review.

2.4. Statistical analysis

Data were analyzed using SPSS software, version 20.0 (IBM Corp, Armonk, NY). Descriptive data were presented as mean ± standard deviation or percent. Continuous and categorical variables were compared by Student’s t-test and chi-square respectively. p < 0.05 was taken statistically significant.

3. Results

3.1. Case report

A 54-year-old male patient was hospitalized 45 days ago due to severe COVID-19 pneumonia. During the hospitalization and especially in the intensive care unit, systemic steroid was administered parenterally. Daily 1 gr methylprednisolone was given at first 3 days of respiratory failure. He was discharged with oral methylprednisolone and it was ceased in the 15th day of treatment (Fig. 2). Two days later, he was admitted to the hospital with severe headache, imbalance, visual impairment and edema evident in right side of the face. He was conscious yet not fully cooperating. Intermittent loss of consciousness was observed. In the MRI images, an opacity which occupy the right maxillary sinus was detected (Fig. 3). Following the deterioration in general status, the patient was intubated. During the intubation, dark-colored necrotizing plaques were seen in the roof of the oral cavity.

The biopsy taken from these plaques established the diagnosis of mucormycosis. He died due to mucormycosis two months after the COVID-19 infection.

3.2. Review on published cases of COVID 19 and mucormycosis

Our literature search of databases (PUBMED, Web of Science, and Scopus) yielded 44 reports. Unrelated publications were omitted and remaining 30 publications (24 case reports and 6 case series) were evaluated. (Fig. 1). All case reports have been reported after 2020 following COVID-19 pandemic. Papers were published in 2020 (n = 7) and in 2021 (n = 23).

The papers (case reports and case series) reported 100 patients including present case report (Table 1) [10–39]. The majority of the patients were presented from India (7 case reports and 5 case series, a total of 68, 68%), followed by Turkey (12), USA (9), Iran (3), Spain (2), United Kingdom (1), Brasil (1), Italy (1), France (1), Mexico (1), and Austria (1). Among case series, five were retrospective and one was prospective. Range of age was 22 years–86 years. Seventy six percent were male. At least one risk factor was noted in 94% of reported cases.

The most commonly seen comorbidities were diabetes (n = 79, 79%), followed by hypertension (n = 34, 34%), and chronic kidney disease (n = 8, 8%). Obesity was noted in 2 cases (2%). Corticosteroid use for COVID-19 diseases was not defined for 5 patients; not used for 9 patients and was used for 86 patients (90.5%). However, the doses were not clearly defined. Antibiotic data were available for 32 cases: 21 were given broad-spectrum antibiotics, in 11 cases, the type of antibiotic was not mentioned. Mucormycosis developed during COVID-19 infection in 53%, while it developed in post-COVID-19 period in remaining 47%. Among these patients, 16 and 1 patients had severe COVID-19 or ARDS in the former and the latter groups respectively. Most frequent involvement sites of mucormycosis were rhino-orbital in 50 (50%), rhino-sinusal in 17 (17%), and rhino-orbito-cerebral in 15 (15%) (Table 2).
The diagnosis was established postmortem in two. The diagnoses were classified proven in 71 (71%) and probable in 29 (29%). Death was reported 33 out of 99 patients (33.3%); one patient’s outcome was not described.

4. Discussion

Our literature search found 99 patients with COVID-19-associated mucormycosis. Patients were given steroid and had diabetes in the majority. The reports were mainly from India. The eye and/or brain involvement was seen in 72%. This deadly combination of COVID-19 and mucormycosis caused death of nearly one third of the patients.

Mucormycosis is extremely rare in otherwise healthy individuals, while it is seen patients with predisposing conditions including uncontrolled diabetes (with or without diabetic ketoacidosis), hematological and other malignancies, organ transplantation, prolonged neutropenia, immunosuppressive and corticosteroid use, iron overload or hemochromatosis, deferoxamine therapy, severe burns, acquired immuno-deficiency syndrome (AIDS), intravenous drug abusers, and open wound following trauma [40]. Recent accumulating reports suggested an increasing prevalence of mucormycosis in COVID-19 patients. In the pathophysiology of mucormycosis in COVID-19 patients, beside the evident roles of ketoacidosis, high blood sugar levels, iron metabolism, long-term use of antibiotics, steroid use and mechanical ventilation of the host, some other factors were suggested to play a role: the role of ferritin which is high in most of the COVID-19 cases, high serum iron, endothelitis induced by free radicals, hepcidin activation through viral mimicry, and upregulation of glucose receptor protein (GRP78) [41].

Increasing mucormycosis cases may be partially explained by increasing steroid use in COVID-19 patients. Steroid use was accelerated after publication of randomized-controlled trial of RECOVERY study [40]. The study showed that for patients hospitalized with COVID-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone. Although steroids have no benefit in patients who do not require respiratory support in the trial, many patients with COVID-19 not requiring mechanical ventilation have been treated with glucocorticoids, even with higher doses and longer durations than recommended in the trial [42]. In the current analysis, 90.5% of patients with mucormycosis and COVID-19 were given steroids (Table 1). Diabetes is
| Author(s) | References | Year | Country | Case number | Age (years) | Gender | Systemic diseases | Pulmonary involvement of COVID-19 | Type of Macromycosis | Diagnosis | Probable or Proven | Post COVID | Steroid use | Antibiotic use | Tocilizumab use | Medical Treatment | Surgical treatment | Outcome |
|-----------|------------|------|---------|-------------|-------------|--------|-------------------|-----------------------------|----------------------|-----------|----------------|-----------|-------------|----------------|----------------|----------------|----------------|---------|
| Hanley B et al. | [10] | 2020 | UK | Case 1 | 22 | M | No | Yes | ARDS | Disseminated | Post mortem | Proven | No | NA | NA | NA | NA | Death |
| Mehta S et al. | [11] | 2020 | India | Case 1 | 60 | M | DM | Yes | ARDS | Rhino-orbital | Nasal biopsy and culture | Proven | No | Yes | Meropenem, oseltamivir | NA | (400 mg) | Amphotericin B | No | Death |
| Mekonnen ZK et al. | [12] | 2020 | USA | Case 1 | 60 | M | DM, asthma, HT, hyperlipidemia | Yes | ARDS | Rhino-orbital | Biopsy and culture: *Rhizopus* spp. | Proven | No | Yes | Vancomycin, ceftazidime | NA | No | No | Death |
| Monte Junior ESD et al. | [13] | 2020 | Brasil | Case 1 | 86 | M | HT | Yes | Gastrointestinal | ARDS | Proven | No | Yes | Meropenem, oseltamivir, cefepime | No | No | No | Death |
| Pasero D et al. | [14] | 2020 | Italy | Case 1 | 66 | M | DM, HT | Yes | Pulmonary | ARDS | Proven | No | No | Piperacillin/tazobactam, levofloxacin, caspofungin | No | No | No | Death |
| Mekonnen ZK et al. | [12] | 2020 | USA | Case 1 | 60 | M | DM, asthma, HT, hyperlipidemia | Yes | ARDS | Rhino-orbital | Biopsy and culture: *Rhizopus* spp. | Proven | No | Yes | Meropenem, oseltamivir, cefepime | NA | No | No | Death |
| Monte Junior ESD et al. | [13] | 2020 | Brasil | Case 1 | 86 | M | HT | Yes | Gastrointestinal | ARDS | Proven | No | Yes | Meropenem, oseltamivir, cefepime | NA | No | No | Death |
| Pasero D et al. | [14] | 2020 | Italy | Case 1 | 66 | M | DM, HT | Yes | Pulmonary | ARDS | Proven | No | No | Piperacillin/tazobactam, levofloxacin, caspofungin | No | No | No | Death |
| Monte Junior ESD et al. | [13] | 2020 | Brasil | Case 1 | 86 | M | HT | Yes | Gastrointestinal | ARDS | Proven | No | Yes | Meropenem, oseltamivir, cefepime | NA | No | No | Death |
| Pasero D et al. | [14] | 2020 | Italy | Case 1 | 66 | M | DM, HT | Yes | Pulmonary | ARDS | Proven | No | No | Piperacillin/tazobactam, levofloxacin, caspofungin | No | No | No | Death |
| Monte Junior ESD et al. | [13] | 2020 | Brasil | Case 1 | 86 | M | HT | Yes | Gastrointestinal | ARDS | Proven | No | Yes | Meropenem, oseltamivir, cefepime | NA | No | No | Death |
| Pasero D et al. | [14] | 2020 | Italy | Case 1 | 66 | M | DM, HT | Yes | Pulmonary | ARDS | Proven | No | No | Piperacillin/tazobactam, levofloxacin, caspofungin | No | No | No | Death |
| Monte Junior ESD et al. | [13] | 2020 | Brasil | Case 1 | 86 | M | HT | Yes | Gastrointestinal | ARDS | Proven | No | Yes | Meropenem, oseltamivir, cefepime | NA | No | No | Death |
| Pasero D et al. | [14] | 2020 | Italy | Case 1 | 66 | M | DM, HT | Yes | Pulmonary | ARDS | Proven | No | No | Piperacillin/tazobactam, levofloxacin, caspofungin | No | No | No | Death |
| Monte Junior ESD et al. | [13] | 2020 | Brasil | Case 1 | 86 | M | HT | Yes | Gastrointestinal | ARDS | Proven | No | Yes | Meropenem, oseltamivir, cefepime | NA | No | No | Death |
| Pasero D et al. | [14] | 2020 | Italy | Case 1 | 66 | M | DM, HT | Yes | Pulmonary | ARDS | Proven | No | No | Piperacillin/tazobactam, levofloxacin, caspofungin | No | No | No | Death |
| Monte Junior ESD et al. | [13] | 2020 | Brasil | Case 1 | 86 | M | HT | Yes | Gastrointestinal | ARDS | Proven | No | Yes | Meropenem, oseltamivir, cefepime | NA | No | No | Death |
| Pasero D et al. | [14] | 2020 | Italy | Case 1 | 66 | M | DM, HT | Yes | Pulmonary | ARDS | Proven | No | No | Piperacillin/tazobactam, levofloxacin, caspofungin | No | No | No | Death |

(continued on next page)
| Author(s) | References Year | Country | Publication type | Case numbers | Age (years) | Gender | Systemic diseases | Pulmonary involvement of COVID-19 | Type of Mucormycosis | Diagnosis | Probable or Proven | Post COVID Steroid use | Antibiotic use | Tocilizumab use | Medical Treatment | Surgical treatment | Outcome |
|-----------|-----------------|---------|-----------------|--------------|-------------|--------|------------------|-------------------------------|---------------------|-----------|-----------------|----------------------|---------------|-----------------|-----------------|-------------------|---------|
| Kanwar A et al. | [24] 2021 USA | Case | 1 | 56 | M | End-stage kidney disease | Yes ARDS | Pulmonary | Culture | Proven | Yes | Yes | Piperacillin/tazobactam, vancomycin | Yes (single dose) | Amphotericin B | No | Death |
| Karimi-Galougahi M et al. | [25] 2021 Iran | Case | 1 | 61 | F | DM | Yes | Rhino-orbital | Histopathology | Proven | Yes | Yes | Vancomycin, meropenem | No | Amphotericin B, posaconazole | Surgical debridement | Death |
| Khatri A | [26] 2021 USA | Case and review of literature | 1 | 68 | M | Orthotopic heart transplantation, CAD | Yes | Pulmonary | Culture: Rhizopus microsporus | Proven | Yes | Yes | Piperacillin/tazobactam, metronidazole | No | Amphotericin B | Surgical debridement | Alive |
| Maini A et al. | [27] 2021 India | Case | 1 | 38 | M | No | Yes | Rhino-orbital | Culture: Rhizopus oryzae | Proven | Yes | Yes | Piperacillin/tazobactam | No | Amphotericin B | Surgical (n = 17), alive (n = 10), death (n = 6), NA (n = 1) |
| M B et al. | [28] 2021 India | Cases series | 17 | 54.6 (35–73) | M (n = 15), F (n = 2) | DM (n = 15) | Yes | Rhino-orbital (n = 6), rhino-orbito-cerebral (n = 5), rhino-cerebral (n = 3), Rhino-sinusal (n = 3) | KOH test and culture (n = 17) | Proven (n = 17), no (n = 5), NA (n = 15) | No | No | Conventional antibiotics | No | Amphotericin B | Surgical (n = 17), alive (n = 10), death (n = 6), NA (n = 1) |
| Nehara HR et al. | [29] 2021 India | Cases series | 5 | 62.2 (52–70) | M (n = 5), DM (type 2) (n = 2), HT (n = 2) | DM (type 2) (n = 5), F (n = 4) | M | DM (n = 5) | Rhizopus-sinusal (n = 5) | LCB & KOH Mount of Nasal Culture (n = 5) | Proven (n = 5), No (n = 5), NA (n = 1) | Yes | Yes | Amphotericin B | No | Amphotericin B | Debridement (n = 2), no (n = 3), Death (n = 2), no (n = 3), Alive |
| Rao R et al. | [30] 2021 India | Case | 1 | 66 | M | DM | Yes | Rhino-orbital | Nasal swab confirmed (KOH) | Proven | No | No | Amphotericin B | No | Orbital exenteration | FESS | Alive |
| Revannavar SM et al. | [31] 2021 India | Case | 1 | Middle-aged | 34, 50 | M (n = 2) | DM (type 2) (n = 2), HT (n = 1) | Maxillo-facial (n = 2) | histopathological examination (n = 2) | Proven (n = 2), No (n = 2), NA (n = 2) | Yes | No | Amphotericin B | No | Amphotericin B (n = 2) | Surgical resection (n = 2) |
| Sai Krishna D et al. | [32] 2021 India | Two cases | 2 | 34, 50 | M (n = 2) | DM (type 2) (n = 2), HT (n = 1) | Maxillo-facial (n = 2) | histopathological examination (n = 2) | Proven (n = 2), No (n = 2), NA (n = 2) | Yes | No | Amphotericin B | No | Conventional amphotericin B | Endoscopic sinus surgery | Alive |
| Sarkar S et al. | [33] 2021 India | Cases series | 10 | 45.5 (23–67) | M (n = 10), DM (n = 10) | M (n = 10), DM (n = 2) | F (n = 2) | Yes | Rhino-orbital (n = 10) | Radiological (n = 4), tissue biopsy (n = 4), nasal swab (n = 2) | Proven (n = 4), No (n = 6), No (n = 10) | Yes | No | Amphotericin B | No | Endoscopic sinus surgery | Alive |
| Sen M et al. | [34] 2021 India | Case Series | 5 | 58 (46–73) | M (n = 5), DM (n = 5), HT (n = 2), CAD (n = 1) | Rhizopus-cerebral (n = 1) | Rhino-orbital (n = 4) | Histopathology | Proven (n = 5), No (n = 1), No (n = 10), No (n = 1) | Yes (n = 4), No (n = 1) | NA | Systemic antibiotics | No | Amphotericin B | Surgical debridement | Alive |
| Sharma S et al. | [35] 2021 India | Case series | 23 | NA | M (n = 15), F (n = 8) | DM (n = 21), HT (n = 14), renal failure (n = 1) | No | Rhizopus-cerebral (n = 2) | Radiological | Proven (n = 23), No (n = 4), No (n = 23) | Yes (n = 19) | Yes (n = 4) | Amphotericin B | No | Amphotericin B (n = 23) | 23 surgical debridement | Alive |

(continued on next page)
### Table 1 (continued)

| Author(s) | References | Year | Country | Publication type | Case numbers | Age (years) | Gender | Systemic diseases | Pulmonary involvement of COVID-19 | Type of Mucormycosis | Diagnosis | Probable or Proven | Post COVID | Steroid use | Antibiotic use | Tocilizumab use | Medical Treatment | Surgical treatment | Outcome |
|-----------|------------|------|---------|-----------------|--------------|-------------|---------|------------------|----------------------------------|----------------------|-----------|-----------------|------------|-------------|----------------|---------------|----------------|---------------------|---------|
| Veisi A et al. [37] | 2021 Iran | Case | 2 | 54, 40 | M (n – 1) DM (n – 1) F (n – 1) | Yes | Rhino-orbital (n – 1) Rhino-orbito-cerebral (n – 1) | Histopathologic and radiologic (n – 2) | Proven (n – 2) No (n – 2) Yes (n – 2) | Meropenem, vancomycin (n – 1) Levofloxacin then piperacillin/tazobactam, vancomycin (n – 1) | No | Amphotericin B | Endoscopic debridement | Death (n – 1), alive (n – 1) |
| Waizel-Haiat S et al. [38] | 2021 Mexico | Case | 1 | 24 | F | Obesity | Yes | Rhino-orbital | Culture: Lichtheimia (Absidia) spp | Proven | No | NA | Amoxicillin-clavulanate (n – 1) Piperacillin/tazobactam, linezolid (n – 1) | NA | Amphotericin B | No | Death |
| Zurl C et al. [39] | 2021 Austria | Case | 1 | 53 | M | MDS, obesity and depression | Yes | ARDS | Pulmonary | Autopsy: Rhizopus microsporus | Proven | No | Yes | Intravenous voriconazole | No | Death |
| Current report | 2021 Turkey | Case | 1 | 54 | M | No | Yes | Maxillo-facial | Histopathologic and radiologic | Proven | Yes | Yes | Ampicillin/sulbactam, clindamycin (n – 1) | No | No | No | Death |

HT: hypertension, UK: United Kingdom, ARDS: acute respiratory distress syndrome, NA: not available, DM: diabetes mellitus, USA: United States of America, BAL: bronchoalveolar lavage, CAD: coronary artery disease, FESS: functional endoscopic sinus surgery, CRF: chronic renal failure, KOH: potassium hydroxide, LCB: lactophenol cotton blue, MSD: myelodysplastic syndrome.
The hot and humid environment India may have promoted growth of fungi, especially in patients with diabetes. During the COVID-19 pandemic, India experienced another pandemic of mucormycosis, which added new risk factors to increasing mucormycosis cases. India has the second largest diabetic population in the world, with 70% of these diabetics being uncontrolled [43].

Environmental factors of tropical and sub-tropical humid climate and high environmental temperature in most parts of India also appeared to contribute to mucormycosis [44]. The vast majority of COVID-19-induced mucormycosis cases was reported from India. Mucormycosis cases were already increasing in India before the pandemic [43]. Many Indian centres have published series of mucormycosis in patients with varying risk factors. This high incidence has been primarily linked to increase in patient population with uncontrolled diabetes [43]. India has the second largest diabetic population of the world (65.1 million), and nearly 70% of these diabetics are uncontrolled [43].

The hot and humid environment India may have promoted growth of mucormycosis species [42]. Hypoxia of the tissues in COVID-19 disease can be another contributing factor. Low oxygen levels in the tissues in addition to the partial infraction of fungal angioinvasion deepens the tissue damage. Also, overuse of antibiotics which is common in COVID-19 management suppresses the normal bacterial flora and facilitates establishment and invasion of fungi. In this systematic review it is shown that broad-spectrum antibiotic use is common in cases of COVID-19 with mucormycosis. Langford et al. [46] found that the prevalence of antibiotics use was 74.6% in COVID cases. Analysis of the registry, SEMI-COVID, showed that 78.1% of COVID patients were prescribed antibiotics whereas 34% of antibiotic prescriptions were inappropriate [47]. Although use of antibiotics has been shown ineffective, an estimated 216 million excess doses antibiotics and 6.2 million azithromycin treatment courses were attributed to COVID-19 during the first wave of COVID-19 in India [42].

The treatment of COVID-19-associated mucormycosis includes a timely combination of surgery and antifungal therapy. Surgery is sino-nasal debridement in most of the cases. Pal et al. [48] compared deceased and survived COVID-19 mucormycosis patients in their systematic review and showed that surgery combined with antifungal therapy was associated with higher survival rates.

5. Conclusion

Current literature review showed that mucormycosis in COVID-19 context is a growing challenge. The majority of the patients are reported from India. Beside ongoing risks of mucormycosis including high incidence of uncontrolled diabetes and environmental conditions, COVID-19 pandemic added new factors such as steroid use, excessive use of antibiotics, and hypoxia. Despite medical and surgical treatment, mortality rate is high. Therefore, clinical guidelines should be implanted for appropriate use of antibiotics in COVID-19 cases. A multidisciplinary approach is essential to improve the conditions facilitating the emergence of mucormycosis among COVID-19 patients.

Funding

There was no specific funding for this project.

Conflict of interest/funding/role of the funding source

All authors declare no conflict of interest.

CRediT authorship contribution statement

Ahmet Dilek and Mustafa Sunbul: Screened all papers, compiled the tables, revising the manuscript critically for important intellectual content. All co-authors contributed to, and endorsed, the final version of the manuscript.

Resat Ozaras and Elif Itir Sen: Writing - original draft, revising the manuscript critically for important intellectual content. All co-authors contributed to, and endorsed, the final version of the manuscript.

Sevket Ozkaya: The patient’s pulmonology physician. Writing - original draft, revising the manuscript critically for important intellectual content. All co-authors contributed to, and endorsed, the final version of the manuscript.

Hakan Leblebiciglu: Senior author. Writing - original draft, designed the study, conducted the literature searches, revising the manuscript critically for important intellectual content. All co-authors contributed to, and endorsed, the final version of the manuscript.

Table 2

| Involvement site          | Number of patients |
|---------------------------|--------------------|
| Rhino-orbital             | 50                 |
| Rhino-sinusal             | 17                 |
| Rhino-orbito-cerebral     | 15                 |
| Pulmonary                 | 8                  |
| Rhino-cerebral            | 4                  |
| Maxillo-facial            | 3                  |
| Disseminated              | 1                  |
| Gastrointestinal          | 1                  |
| Musculoskeletal           | 1                  |

References

[1] Bhakt K, Agoli A, Patel MH, et al. High mortality co-infections of COVID-19 patients: mucormycosis and other fungal infections. Discoveries 2021;9:e126.
[2] Song G, Liang G, Liu W. Fungal Co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China. Mycopathologia 2020; 185:599–606.
[3] Thevissen K, Jacobs C, Holtappels M, Toda M, Verweij P, Wantjes J. International survey on influenza-associated pulmonary aspergillosis (IAPA) in intensive care units: responses suggest low awareness and potential underdiagnosis outside Europe. Crit Care 2020;24:84.
[4] Schauwvlieghe A, Rijnders RJ, Philips N, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med 2018;6:782–92.
[5] Mitaka H, Kuno T, Takagi H, Patrawalla P. Incidence and mortality of COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis. Mycoses 2021;64(9):1001. https://doi.org/10.1111/myc.13292.
[6] Ravani SA, Agrawal GA, Leuwa PA, Modi PH, Amin KD. Rise of the phoenix: mucormycosis in COVID-19 times. Indian J Ophthalmol 2021;69:1563–8.
[7] Chong WH, Neu KP. Incidence, diagnosis and outcomes of COVID-19-associated pulmonary aspergillosis (CAPA): a systematic review. J Hosp Infect 2021;113:115–29.
[8] Honavar SG. Code macor: guidelines for the diagnosis, staging and management of rhino-orbito-cerebral mucormycosis in the setting of COVID-19. Indian J Ophthalmol 2021;69:1361–5.
[9] Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:z711.
[10] Hanley B, Naresh KN, Rowfode C, et al. Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. Lancet Microbe 2020;1:e245–53.
[11] Mehta S, Pandey A. Rhino-orbital mucormycosis associated with COVID-19. Cureus 2020;12:e10726.
[12] Meckonen ZK, Ashraf DC, Jankowski T, et al. Acute invasive rhino-orbital mucormycosis in a patient with COVID-19-associated acute respiratory distress syndrome. Ophthalmic Plast Reconstr Surg 2021;37:e40–80.
[13] Monte Junior ISD, Santos M, Ribeiro IB, et al. Rare and fatal gastrointestinal mucormycosis (zygomycosis) in a COVID-19 patient: a case report. Clin Endosc 2020;53:746–9.
[14] Paisero D, Sanna S, Liperi C, et al. A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis. Infection 2020;1–6.
[28] Moorthy A, Gaikwad R, Krishna S, et al. SARS-CoV-2, uncontrolled diabetes and COVID-19 pneumonia. J Med Cases 2021;12:85-9.

[29] Revannavar SM, P SS, Samaga I, V KV. COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world? BMJ Case Rep 2021;4.

[30] Sai Krishna D, Raj H, Kurup F, Janeja M. Maxillofacial infections in COVID-19 era: actuality or the unforeseen? BMJ Case Rep 2022:1-4.

[31] Saldanha LO, Ozzello DJ, Liu CY, Kikkawa DO, Korn BS. Secondary infection with rhino-orbital cerebral mucormycosis associated with COVID-19. Orbit 2021: 1-4.

[32] Garg D, Muthu V, Sehgal IS, et al. Coronavirus disease (COVID-19) associated mucormycosis (CAM): case report and systematic review of literature. Mycopathologia 2021;186:289-98.

[33] Johnson AK, Ghazarian Z, Cendrowski KD, Persichino JG. Pulmonary aspergillosis and mucormycosis in a patient with COVID-19. Med Mycol Case Rep 2021;32: 64-7.

[34] Kamvar A, Jordan A, Olerwiler S, Webberg K, Cortes M, Jackson BR. A fatal case of rhizopus arzzygosporus pneumonia following COVID-19. J Fungi (Basel) 2021;7.

[35] Singh AA, Singh R, Joshi SR, Misrac A. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes Metab Syndr 2021;15:98-109.

[36] Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. J Laryngol Otol 2021: 1-6.

[37] Veisi A, Bagheri A, Esbaghi M, Rikhthegar MH, Rezaei Kanavi M, Farjad R. Rhino-orbital mucormycosis following COVID-19: a case report. J Otolaryngol Head Neck Surg 2021:1-4.

[38] Wang J, Song X, Li Y, et al. Mucormycosis: a deadly trio: case series from the north-western part of India. Indian J Med Microbiol 2021;39(3):380-3. https://doi.org/10.1016/j.ijmmib.2021.05.009.

[39] Rao R, Shetty AP, Nagesh CP. Orbital infarction syndrome secondary to rhino-orbital mucormycosis in a case of COVID-19: clinico-radiological features. Indian J Ophthalmol 2021;69:1627-30.

[40] Sugar AM. Mucormycosis. Clin Infect Dis 1992;14(Suppl 1):S126-S8.

[41] Chakrabarti A, Singh R. Mucormycosis in India: unique features. Mycoses 2014;57(13):797-801.

[42] Langford BJ, So M, Raybardhan S, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect 2021;27:520-526.

[43] Calderon-Parra J, Muino-Miguez A, Bendala-Estrada AD, et al. Inappropriate antibiotic use in the COVID-19 era: factors associated with inappropriate prescribing and secondary complications. Analysis of the registry SEMI-COVID. PLoS One 2021;16:e0251340.

[44] Pal R, Singh B, Bhardoa SK, et al. COVID-19-associated mucormycosis: an updated systematic review of literature. Mycoses 2021. https://doi.org/10.1111/myc.13338. Online ahead of print.